Mahmood Naderi

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Endoplasmic Reticulum Stress

Squamous Cell Carcinoma

Top Venues

Cancer immunology, immunotherapy : CII

Journal of cellular biochemistry

Expert opinion on therapeutic targets

This page only lists publications with an associated author ORCID identifier.

Publications

Masoud Sotoudeh, Vahid Mansouri, Ramin Shakeri, Bahareh Sharififard, Nasim Sajadi, Vahid Haghpanah, Mahmood Naderi
Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy. Expert opinion on therapeutic targets (2023)
Masoud Sotoudeh, Vahid Mansouri, Ramin Shakeri, Bahareh Sharififard, Nasim Sajadi, Mahmood Naderi
Interpatient variability in mesothelin expression necessitates its evaluation before gastric cancer immunotherapy. Immunotherapy 14 (7) (2022)
Fatemeh Ghafouri, Reza Ahangari Cohan, Hilda Samimi, Ali Hosseini Rad S M, Mahmood Naderi, Farshid Noorbakhsh, Vahid Haghpanah
Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study. JMIR bioinformatics and biotechnology 3 (1) (2022)
Masoud Sotoudeh, Ramin Shakeri, Sanford M Dawsey, Bahareh Sharififard, Naser Ahmadbeigi, Mahmood Naderi
ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy. Cancer immunology, immunotherapy : CII 68 (10) (2019)
Masoud Sotoudeh, Seyed Iman Shirvani, Shahin Merat, Naser Ahmadbeigi, Mahmood Naderi
MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. Journal of cellular biochemistry 120 (4) (2018)